Browsing by Author "Heintz, B."
Now showing items 1-4 of 4
-
Endothelin-1 plasma levels in hemodialysis treatment - The influence of type 2 diabetes
Liakopoulos, V.; Wurth, P.; Mertens, P. R.; Eleftheriadis, T.; Kourti, P.; Voliotis, G.; Heintz, B.; Koukoulis, G. N.; Stefanidis, I. (2005)In patients on chronic hemodialysis the prevalence of atherosclerosis is increased and is by far the leading cause of morbidity and mortality. Endothelin-1, an endothelium-derived peptide with vasoconstrictive and mitogenic ... -
Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease
Liakopoulos, V.; Eleftheriadis, T.; Kyropoulos, T.; Voliotis, G.; Potamianos, S.; Zengos, N.; Stefanidis, I.; Heintz, B. (2005)Atherosclerosis is by far the leading cause of mortality and morbidity in patients with end stage renal disease undergoing chronic hemodialysis (HD). Vascular endothelial cell adhesion molecules like the intercellular ... -
Influence of hemodialysis on the mean blood flow velocity in the middle cerebral artery
Stefanidis, I.; Bach, R.; Mertens, P. R.; Liakopoulos, V.; Liapi, G.; Mann, H.; Heintz, B. (2005)Background: Several effects of hemodialysis, including hemoconcentration, alterations of hemostasis or hemorheology and endothelial activation, could potentially interfere with cerebral blood flow (CBF) regulation. These ... -
Plasma endothelin-1 in hemodialysis treatment - the influence of hypertension
Stefanidis, I.; Wurth, P.; Mertens, P. R.; Ikonomov, V.; Philippidis, G.; Golphinopoulos, S.; Makropoulos, V.; Liakopoulos, V.; Mann, H.; Heintz, B. (2004)In patients on chronic hemodialysis hypotensive episodes are frequently encountered during the course of treatment and the prevalence of atherosclerosis is increased. Endothelin-1 (ET-1), an endothelium-derived peptide ...